Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Cathinone or [[:Category:Amphetamines|Amphetamine]]

Use the filters below to narrow your results.

generic:
3-MMC (1) · Butylone (1) · Cathinone (1) · Ephylone (1) · Ethcathinone (1) · Ethylone (1) · Hexedrone (1) · Lisdexamfetamine (dimesylate) (1) · Mephedrone (1) · Methcathinone (1) · Methylone (1) · Mexedrone (1) · N-Ethylhexedrone (1) · N-Ethylpentedrone (1) · Pentedrone (1)
brand:
None (14) · Vyvanse, Elvanse (EU) (1)
classes: (Click arrow to add another value)
mechanism:
Cathinone analogue; monoamine reuptake inhibitor (2) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · '"`UNIQ--vote-00000013-QINU`"' Once converted, dextroamphetamine acts by displacing dopamine and norepinephrine from presynaptic vesicles via VMAT-2 and reversing DAT and NET transport, the shared mechanism of all amphetamine-class agents'"`UNIQ--ref-00000014-QINU`"'. (1)
uses:
None (14) · '"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"' (1)
starting dose:
None (14) · ADHD: 30 mg PO once daily in the morning; titrate by 10-20 mg weekly to clinical effect. Binge-eating disorder: 30 mg/day, titrate to 50-70 mg/day (1)
preparations:
None (14) · Capsules 10, 20, 30, 40, 50, 60, 70 mg; chewable tablets 10, 20, 30, 40, 50, 60 mg (1)
fda max:
None (14) · 70 mg/day (1)
routes:
None (14) · Oral (1)
onset:
None (14) · 1-2 hours (slower than immediate-release amphetamine because activation requires enzymatic cleavage in red blood cells) (1)
duration:
None (14) · 10-12 hours (smoother profile than immediate-release amphetamine salts) (1)
halflife:
None (14) · Parent lisdexamfetamine <1 hour; dextroamphetamine 10-12 hours after release'"`UNIQ--ref-00000017-QINU`"' (1)
bioavailability:
None (14) · ~96% after red blood cell hydrolytic cleavage releases dextroamphetamine'"`UNIQ--ref-00000018-QINU`"' (1)
pregnancy:
None (14) · Limited human data; the amphetamine class is associated with intrauterine growth restriction and neonatal withdrawal symptoms.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (14) · [[USLegal:Schedule II|Schedule II controlled substance]] in US'"`UNIQ--ref-00000019-QINU`"' (1)

Showing below up to 15 results in range #1 to #15.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"